← Back to Search

Monoclonal Antibodies

Bevacizumab for Cervical Cancer

Phase 1

Waitlist Available

Research Sponsored by EMD Serono Research & Development Institute, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up pre-dose up to 20 months

Awards & highlights

Study Summary

This trial will test the safety of a new cancer treatment in women with cervical cancer that has spread.

Eligible Conditions

Cervical Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ pre-dose up to 20 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~pre-dose up to 20 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and pre-dose up to 20 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of Participants With Dose-Limiting Toxicities (DLTs)

Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

Secondary outcome measures

Area Under the Serum Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Bintrafusp Alfa

Area Under the Serum Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Bintrafusp Alfa

Immediate Observed Serum Concentration at End of Infusion (Ceoi) of Bintrafusp Alfa

+7 more

Trial Design

3Treatment groups

Experimental Treatment

Group I: Cohort1B:M7824+Cisplatin or Carboplatin+PaclitaxelExperimental Treatment4 Interventions

Group II: Cohort 2: M7824+Cisplatin+ RadiotherapyExperimental Treatment3 Interventions

Group III: Cohort 1A:M7824+Cisplatin/Carboplatin+Paclitaxel+BevacizumabExperimental Treatment5 Interventions

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Carboplatin

2014

Completed Phase 3

~6670

Paclitaxel

2011

Completed Phase 4

~5380

Bevacizumab

2013

Completed Phase 4

~5280

Cisplatin

2013

Completed Phase 3

~1940

M7824

2020

Completed Phase 2

~350

Radiotherapy

2017

Completed Phase 3

~2610

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

EMD Serono Research & Development Institute, Inc.Lead Sponsor

76 Previous Clinical Trials

30,835 Total Patients Enrolled

Merck KGaA, Darmstadt, GermanyIndustry Sponsor

436 Previous Clinical Trials

114,631 Total Patients Enrolled

Medical ResponsibleStudy DirectorMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

288 Previous Clinical Trials

68,950 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

In which locations is this experiment conducted?

"This trial is currently conducted in 5 medical centres; Stanford, Cincinnati and Augusta being a few examples. Participants should opt for the closest location to reduce travel inconveniences when enrolling."

Answered by AI

What medical ailments is Bevacizumab commonly utilized to treat?

"Bevacizumab can be used to treat malignant tumours, locally advanced non-squamous NSCLC, and metastasized colorectal cancer."

Answered by AI

Is there any evidence that Bevacizumab may be detrimental to human health?

"The safety of Bevacizumab was evaluated by our team at Power, and a rating of 1 was assigned due to the Phase I trial status, thus indicating only minimal clinical data verifying its efficacy as well as security."

Answered by AI

How many participants are enrolled in this research endeavor?

"At present, this clinical trial is not enrolling patients. The study was first published on October 19th 2020 and the information available online has been updated as recently as July 4th 2022. Alternatively, there are 397 trials for cervical cancer that require participants and 1811 investigations utilising Bevacizumab still looking to recruit individuals."

Answered by AI

Are there still openings for this research trial?

"This clinical trial has concluded its recruitment period and is no longer searching for participants. It was initially published on October 19th 2020, with the last update made on July 4th 2022. As an alternative, 397 trials are currently enrolling patients diagnosed with cervical cancer while 1811 studies require Bevacizumab-users as test subjects."

Answered by AI

Are there any other experiments that have featured Bevacizumab as a central element?

"In 1997, City of Hope Comprehensive Cancer Center first initiated research on bevacizumab. Now 3157 trials have been completed and 1811 are still ongoing - a large portion of which take place in Stanford, California."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)

2020. "Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04551950.